Earnings Releases·Nov 4, 2026, 7:38 AM ET

Royalty Pharma — Q3 2026 Earnings Summary

Portfolio Receipts grew 9% year-over-year to $890 million, while Adjusted EBITDA rose 8% to $840 million; however, net income declined to $145 million from $284 million due to a $150 million non-cash impairment charge related to pelacarsen.
Full year 2026 Portfolio Receipts guidance was raised to $3,500 million–$3,550 million (previously $3,400 million–$3,500 million), with Royalty Receipts growth expected at 10%–11% and operating costs guidance tightened to 5.5%–6.0% of receipts.
Royalty Receipts were driven by double-digit growth in Tremfya (61%), Voranigo (65%), and Evrysdi (38%), partially offset by declines in Promacta (-75%) and Imbruvica (-24%) due to generic competition and lower sales.
Capital deployment totaled $1.2 billion for the nine months ended September 30, 2026, with new acquisitions including Arcutis' Zoryve and Takeda's Mimrylo, alongside $1 billion in R&D co-funding transactions announced in 2026.
The company returned capital via a $135 million quarterly dividend ($0.235/share) and share repurchases of $87 million in Q3 ($183 million YTD), while reducing total debt principal to $8.8 billion from $9.2 billion in June 2026.